Thrombocytosis and thrombosis

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Thrombocytosis, or elevated platelet counts, is often linked to chronic myeloproliferative disorders (CMPD).
• Specific molecular mutations, including JAK2V617F and MPLW515L/K, are increasingly identified in CMPD patients.
• Distinguishing primary thrombocytosis from reactive causes and classifying CMPD subtypes remains challenging.

Purpose of the Study:

• To review current diagnostic strategies for thrombocytosis.
• To integrate new molecular findings into the classification of CMPD.
• To discuss the role of thrombocytosis in thrombosis and hemorrhage.

Main Methods:

• Literature review of diagnostic approaches for thrombocytosis.
• Analysis of molecular abnormalities (JAK2V617F, MPLW515L/K) in CMPD.
• Evaluation of bone marrow histology's role in diagnosis.

Main Results:

• JAK2V617F and MPLW515L/K mutations are prevalent in essential thrombocythemia, polycythemia vera, and primary myelofibrosis.
• These mutations are not universally present or disease-specific, necessitating a comprehensive diagnostic approach.
• Bone marrow histology is crucial for differentiating CMPD subtypes and reactive thrombocytosis.

Conclusions:

• Despite molecular discoveries, a multifaceted diagnostic approach including bone marrow histology is essential for thrombocytosis.
• Understanding molecular drivers like JAK2V617F aids in risk stratification for thrombosis and hemorrhage.
• Current and emerging management strategies for thrombocytosis are critical for patient outcomes.